课题基金 / 基金详情

DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF CTLA4IG IN PATIENTS WITH PSORIASIS

DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF CTLA4IG IN PATIENTS WITH PSORIASIS
CTLA4IG 在银屑病患者中的双盲、安慰剂对照研究
批准号：
6116980
负责人：
JON M HANIFIN
金额：
$3.13万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6116980
关键词：
clinical research drug screening /evaluation human subject human therapy evaluation immunoconjugates immunotherapy pharmacokinetics psoriasis

项目摘要

项目成果

JON M HANIFIN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This Phase II study is a multi-center, randomized, placebo-controlled trial designed to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and biologic activity of BMS-188667 (CTLA4Ig) in patients with psoriasis vulgaris. Eligable patients will have stable plaque psoriasis of greater than six months duration, and involvement of at least 10% body surface area (BSA), and will have failed at least one standard anti-psoriatic therapy for toxicity and/or inefficacy. Information from this study will be used in the development of dosing schedules in Phase III studies in this patient population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
International Symposium on Atopic Dermatitis
DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF CTLA4IG IN PATIENTS WITH PSORIASIS
MONOCYTE CONTROL OF IL 4 EXPRESSION IN ATOPIC DERMATITIS
MONOCYTE CONTROL OF IL 4 EXPRESSION IN ATOPIC DERMATITIS